An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the <i>UBE3A-AS</i> transcriptScott V. Dindot, Jill L. Silverman, Jennifer Panagoulias et al.|Science Translational Medicine|2023Cited by 95
Rodent Models and How They Define Potential Human Benefit: A Translational Review for Angelman SyndromeKelly M. Knee, Allyson Berent, Edwin J. Weeber et al.|Unknown|2026Cited by 1